<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02536456</url>
  </required_header>
  <id_info>
    <org_study_id>20150823</org_study_id>
    <nct_id>NCT02536456</nct_id>
  </id_info>
  <brief_title>China PEACE Million Persons Project</brief_title>
  <official_title>China PEACE Million Persons Project</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>China National Center for Cardiovascular Diseases</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>China National Center for Cardiovascular Diseases</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      China PEACE Millions Persons Project is a national screening project for cardiovascular&#xD;
      disease in China. This Project was approved by National Health and Family Planning Commission&#xD;
      (NHFPC), China and founded by Ministry of Finance, China in 2014.&#xD;
&#xD;
      The specific objectives of the project are to:&#xD;
&#xD;
        1. identify subjects at high-risk of CVD and provide counseling for medication and&#xD;
           lifestyle improvements&#xD;
&#xD;
        2. evaluate the feasibility of such screening methods for subjects at high risk of CVD, and&#xD;
           to assess the effect of health counseling on CVD incidence rates and risk factors&#xD;
           control&#xD;
&#xD;
        3. inform future intervention and long-term follow up efforts for primary and secondary CVD&#xD;
           prevention in China.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date>July 2014</start_date>
  <completion_date type="Anticipated">July 2021</completion_date>
  <primary_completion_date type="Anticipated">July 2021</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Other</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Incidence of Cardiovascular diseases</measure>
    <time_frame>5 years</time_frame>
    <description>Number of new cardiovascular diseases in high-risk subjects</description>
  </primary_outcome>
  <enrollment type="Anticipated">4000000</enrollment>
  <condition>Cardiovascular Disease</condition>
  <biospec_retention>Samples With DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      For each high-risk subject, a 6mL whole blood sample is collected in an EDTA vacuum tube.A&#xD;
      10mL urine sample is also collected.&#xD;
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        Residents from the communities or villages in selected sites&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. 35 - 75 years old&#xD;
&#xD;
          2. registered in the Hukou of the selected region&#xD;
&#xD;
          3. sign the consent form&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
        -&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>35 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Lixin Jiang, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>China National Center for Cardiovascular Diseases</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Jiapeng Lu, PhD</last_name>
    <phone>0086-10-60866783</phone>
    <email>jiapeng.lu@fwoxford.org</email>
  </overall_contact>
  <location>
    <facility>
      <name>Fuwai hospital</name>
      <address>
        <city>Beijing</city>
        <state>Beijing</state>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Lixin Jiang, MD, PhD</last_name>
      <phone>8610-8839-6203</phone>
      <email>lixin.jiang@fwoxford.org</email>
    </contact>
    <investigator>
      <last_name>Lixin Jiang, MD, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>August 2020</verification_date>
  <study_first_submitted>August 24, 2015</study_first_submitted>
  <study_first_submitted_qc>August 28, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">August 31, 2015</study_first_posted>
  <last_update_submitted>August 13, 2020</last_update_submitted>
  <last_update_submitted_qc>August 13, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">August 17, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>screening</keyword>
  <keyword>counseling</keyword>
  <keyword>follow-up</keyword>
  <keyword>cardiovascular disease</keyword>
  <keyword>population-based project</keyword>
  <keyword>China</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Cardiovascular Diseases</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

